TRAPPC5 Antibody

What is TRAPPC5 and why is it important in cellular research?

TRAPPC5, also known as TRS31, is a 181 amino acid protein belonging to the TRAPP small subunits family and the BET3 subfamily. It is a key component of the multisubunit TRAPP tethering complex that functions as a GTP exchange factor. TRAPPC5 is evolutionarily conserved and plays essential roles in protein binding, vesicle-mediated transport, and nucleotide exchange stimulation . The protein localizes primarily to the Golgi apparatus and is critical for endoplasmic reticulum (ER)-to-Golgi and intra-Golgi vesicle trafficking in yeast. In mammals, TRAPPC5 has expanded functions, including post-Golgi trafficking . Studying TRAPPC5 is crucial for understanding the fundamental mechanisms of intracellular transport and how disruptions in these pathways contribute to various diseases.

What are the common applications for TRAPPC5 antibodies in research?

TRAPPC5 antibodies are valuable tools in several research applications:

• Immunohistochemistry on paraffin-embedded tissues (IHC-p) to visualize TRAPPC5 localization in tissue sections

• Enzyme-linked immunosorbent assay (ELISA) for quantitative detection of TRAPPC5

• Immunofluorescence microscopy to study the subcellular localization of TRAPPC5, particularly in relation to other TRAPP complex components and Golgi markers

• Western blotting to detect TRAPPC5 protein expression levels in different cell types and experimental conditions

• Co-immunoprecipitation studies to investigate TRAPPC5's interactions with other TRAPP complex members

For optimal results in IHC applications, a dilution range of 1:100-200 is recommended, while ELISA applications typically require a 1:5000 dilution .

What is the relationship between TRAPPC5 and the broader TRAPP complex?

TRAPPC5 (TRS31 in yeast) is a core component of the TRAPP complex, which exists in multiple forms (TRAPP I, II, and III) with distinct functions in membrane trafficking. The core TRAPP complex in both yeast and humans includes TRAPPC1, TRAPPC2, TRAPPC3, TRAPPC4, TRAPPC5, TRAPPC6A, and TRAPPC6B, with TRAPPC2L (Tca17p ortholog) specifically found in the TRAPP II complex in yeast .

These components work together to mediate different aspects of vesicular transport. TRAPPC5 is essential for the assembly and function of the TRAPP complex, as demonstrated by studies showing that some TRAPP complex proteins like TRAPPC3, TRAPPC4, and TRAPPC5 cannot complement the loss of their yeast orthologs, highlighting their specialized roles in the complex . Understanding the interactions between TRAPPC5 and other TRAPP components is crucial for elucidating the mechanisms of membrane trafficking in normal and disease states.

How can I validate the specificity of my TRAPPC5 antibody in experimental systems?

Validating antibody specificity is crucial for reliable experimental outcomes. For TRAPPC5 antibodies, consider these methodological approaches:

• Genetic knockdown/knockout validation:

  • Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate TRAPPC5 expression

  • Compare antibody signal in wildtype versus knockdown/knockout samples by Western blot and immunofluorescence

  • Expect significantly reduced or absent signal in knockdown/knockout samples

• Recombinant protein controls:

  • Express tagged recombinant TRAPPC5 (e.g., with His, FLAG, or GFP tags)

  • Perform parallel detection with anti-tag antibodies and your TRAPPC5 antibody

  • Confirm signal co-localization in overexpression systems

• Peptide competition assay:

  • Pre-incubate your TRAPPC5 antibody with the immunizing peptide

  • Compare signal between blocked and unblocked antibody samples

  • Specific antibodies will show significantly reduced signal when blocked with the immunizing peptide

• Cross-reactivity assessment:

  • Test the antibody in cells from different species (human, mouse, rat) if the antibody is reported to be cross-reactive

  • Ensure proper controls for each species are included

For TRAPPC5 antibodies specifically, examine co-localization with known Golgi markers and other TRAPP complex components to confirm proper subcellular localization patterns.

What are the critical factors in designing experiments to study TRAPPC5's role in stress-induced trafficking arrest?

When investigating TRAPPC5's involvement in stress-induced trafficking arrest, several critical experimental design factors should be considered:

• Stress induction protocols:

  • Oxidative stress can be induced with sodium arsenite (SA), which is known to trigger the formation of stress granules (SGs) where TRAPP components relocalize

  • Standardize exposure times and concentrations based on cell type (typically 500 μM SA for 30-60 minutes)

  • Include multiple stress inducers (e.g., heat shock, ER stress) to determine specificity of TRAPPC5 responses

• Temporal dynamics:

  • Implement time-course experiments to capture the kinetics of TRAPPC5 relocalization

  • Monitor both early (5-15 min) and late (1-4 hours) responses

• Co-visualization techniques:

  • Always co-stain with established stress granule markers (e.g., eIF3) to confirm SG formation

  • Use multiple TRAPP complex antibodies to determine if the entire complex or only specific subunits relocalize

  • Include COPII coat components (Sec23/Sec24) in visualization, as TRAPP drives their recruitment to SGs

• Cell cycle considerations:

  • The TRAPP complex and COPII recruitment to SGs is CDK1/2-dependent and only occurs in actively proliferating cells

  • Use cell synchronization methods to analyze TRAPPC5 behavior in different cell cycle phases

  • Include CDK1/2 inhibitors (flavopiridol, dinaciclib, SNS032) at concentrations as low as 100 nM to block relocalization

• Functional readouts:

  • Measure secretory pathway function using cargo trafficking assays (e.g., VSVG-GFP transport)

  • Assess Golgi morphology changes using Golgi markers, as TRAPP complex relocalization leads to Golgi vesiculation

  • Analyze Rab1 activity status, as TRAPP complex functions as a Rab1 GEF and its relocalization to SGs affects Rab1 function

How can I troubleshoot differential localization patterns observed with TRAPPC5 antibodies in stress versus non-stress conditions?

Troubleshooting differential TRAPPC5 localization patterns requires systematic evaluation of both technical and biological factors:

• Fixation and permeabilization optimization:

  • Stress granules and membrane structures require specific fixation protocols

  • Compare paraformaldehyde (PFA) fixation (4%, 10-15 minutes) with methanol fixation (-20°C, 5 minutes)

  • Test different permeabilization reagents (0.1-0.5% Triton X-100, 0.1-0.5% saponin)

  • SGs may be sensitive to certain fixation conditions that can dissolve or alter their morphology

• Antibody incubation conditions:

  • Titrate antibody concentrations separately for stress and non-stress conditions

  • Extended primary antibody incubation (overnight at 4°C) may improve detection in stress granules

  • Include blocking proteins that reduce non-specific binding to RNA-rich stress granules

• Epitope accessibility considerations:

  • TRAPPC5 may undergo conformational changes or interact with different partners under stress

  • Try antibodies targeting different epitopes of TRAPPC5

  • Consider the effects of post-translational modifications that might occur during stress

• Controls for relocalization specificity:

  • Use CDK1/2 inhibitors (flavopiridol, dinaciclib, SNS032) which block TRAPPC5 relocalization to stress granules

  • Include cells at different cell cycle stages, as TRAPPC5 relocalization is cell cycle-dependent

  • Compare wild-type TRAPPC5 localization with disease-associated mutants that show reduced SG association

• Sequential imaging protocol:

  • Image the same field of cells before and after stress induction

  • Use live-cell imaging with fluorescently tagged TRAPPC5 to monitor dynamic relocalization

Remember that in non-stressed cells, TRAPPC5 typically shows diffuse or punctate cytoplasmic localization with Golgi enrichment, while under oxidative stress, it relocalizes to round structures (stress granules) that co-label with eIF3 .

What methodological approaches should I use to investigate TRAPPC5 dysfunction in neurodevelopmental disorders?

Investigating TRAPPC5 dysfunction in neurodevelopmental disorders requires a multi-faceted approach:

• Patient-derived cell models:

  • Establish fibroblast cultures from affected individuals

  • Generate induced pluripotent stem cells (iPSCs) and differentiate to neural lineages

  • Implement CRISPR-Cas9 to introduce or correct TRAPPC5 variants in isogenic cell backgrounds

• Membrane trafficking functional assays:

  • Assess ER-to-Golgi transport using VSVG-GFP temperature-sensitive transport assay

  • Examine Golgi morphology using GM130 or other Golgi markers

  • Measure rates of protein secretion using secreted luciferase reporters

  • Based on findings from other TRAPP components, look for delays in traffic into and out of the Golgi

• Biochemical complex assembly analysis:

  • Perform size exclusion chromatography to assess TRAPP complex assembly, as variants in TRAPP components can affect complex formation

  • Use co-immunoprecipitation to evaluate TRAPPC5 interactions with other TRAPP subunits

  • Apply proximity labeling methods (BioID, APEX) to map the TRAPPC5 interactome in neuronal cells

• Small GTPase activity measurements:

  • Assess RAB1 activation status, as TRAPPC5 is part of complexes with RAB1 GEF activity

  • Examine RAB11 levels, as TRAPP variants have been shown to alter RAB11 activation

  • Use FRET-based biosensors to measure GTPase activity in living cells

• Animal and yeast model systems:

  • Create humanized yeast models expressing human TRAPPC5 or disease variants

  • Develop knockin mouse models with specific TRAPPC5 variants

  • Assess neurodevelopmental endpoints in these models, including neuronal migration, axon guidance, and synapse formation

By integrating these approaches, researchers can establish causative links between TRAPPC5 variants and resulting cellular phenotypes in the context of neurodevelopmental disorders.

How do mutations in different TRAPP complex components (like TRAPPC1, TRAPPC2, TRAPPC5) affect antibody selection and experimental design?

When studying mutations in TRAPP complex components, antibody selection and experimental design must be carefully tailored:

• Antibody epitope considerations:

  • Select antibodies whose epitopes do not overlap with common mutation sites

  • For truncation mutations that create premature stop codons (e.g., TRAPPC1 p.Val121Alafs*3) , use antibodies targeting N-terminal regions

  • For in-frame deletions (e.g., TRAPPC1 p.His22_Lys24del) , confirm the antibody's epitope is not within the deleted region

• Detection of mutant proteins:

  • Validate antibody reactivity against both wild-type and mutant proteins using recombinant expression systems

  • Consider using epitope tagging approaches for mutations that might affect antibody recognition

  • For studies of patient-derived cells, include wild-type controls from related individuals when possible

• Experimental design adjustments:

  • For mutations affecting TRAPP complex assembly, include size exclusion chromatography or native PAGE to assess complex formation

  • For mutations affecting protein-protein interactions, implement yeast two-hybrid assays or in vitro binding studies

  • For mutations in different complex components, design experiments to test functional redundancy using complementation assays

• Comparative analysis across TRAPP components:

  • Include antibodies against multiple TRAPP components in the same experiment

  • Assess potential compensatory changes in other TRAPP components when one is mutated

  • Evaluate the effects of mutations on interactions between different TRAPP proteins

• Humanized yeast models:

  • For comparative studies of mutations across different TRAPP genes, consider using humanized yeast models where human TRAPP genes replace their yeast orthologs

  • This approach allows direct comparison of different mutations in a consistent cellular background

  • Not all human TRAPP genes can functionally replace their yeast orthologs (e.g., TRAPPC3, TRAPPC4, and TRAPPC5 cannot complement the loss of BET3, TRS23, and TRS31)

What methodological approaches should I use to study the role of TRAPPC5 in the integrated stress response?

The integrated stress response (ISR) involves complex cellular adaptations, and studying TRAPPC5's role requires specialized approaches:

• Stress induction protocols:

  • Implement various ISR activators: sodium arsenite (oxidative stress), thapsigargin (ER stress), tunicamycin (ER stress), heat shock

  • Use time-course and dose-response analyses to capture dynamic responses

  • Include recovery phases to assess reversibility of TRAPPC5 relocalization

• TRAPPC5 and stress granule dynamics:

  • Perform live-cell imaging with fluorescently tagged TRAPPC5 and stress granule markers

  • Use FRAP (Fluorescence Recovery After Photobleaching) to assess TRAPPC5 mobility in stress granules

  • Implement optogenetic approaches to locally induce stress granule formation and observe TRAPPC5 recruitment

• CDK1/2 dependency analysis:

  • Use specific CDK1/2 inhibitors (flavopiridol, dinaciclib, SNS032) at concentrations as low as 100 nM

  • Implement siRNA targeting CDK1 and CDK2 to validate inhibitor results

  • Include cell cycle synchronization to examine TRAPPC5 behavior at specific cell cycle stages

• Interactome studies under stress:

  • Perform proteomics analysis of TRAPPC5 interactors under normal and stress conditions

  • Focus on RNA-binding proteins (RBPs) that may mediate TRAPPC5 recruitment to stress granules

  • Examine interactions with specific SG components like hnRNPK, which is a CDK substrate that associates with SGs when phosphorylated

• Secretory pathway functional assessment:

  • Monitor COPII recruitment to stress granules, as TRAPPC5/TRAPP drives this process

  • Assess Golgi morphology changes during stress using Golgi markers

  • Measure secretory cargo transport rates during stress and recovery phases

  • Evaluate Rab1 activity, as TRAPP complex relocalization affects Rab1 function

• Disease-associated variant analysis:

  • Compare wild-type TRAPPC5 with disease-associated mutants of TRAPPC2 (D47Y, R90X) which show reduced or no association with stress granules

  • Assess whether TRAPPC5 mutations similarly affect SG association

  • Evaluate the consequences of altered TRAPPC5 localization on cell survival under stress

What are the optimal protocols for using TRAPPC5 antibodies in different experimental applications?

Immunohistochemistry (IHC-p)

• Deparaffinize and rehydrate tissue sections

• Perform antigen retrieval (typically citrate buffer pH 6.0, 95-98°C for 15-20 minutes)

• Block endogenous peroxidase activity with 3% H₂O₂ in methanol for 10 minutes

• Block non-specific binding with 5% normal serum in PBS for 1 hour at room temperature

• Apply TRAPPC5 antibody at 1:100-200 dilution and incubate overnight at 4°C

• Apply appropriate HRP-conjugated secondary antibody and develop with DAB

• Counterstain, dehydrate, and mount

Western Blotting

• Prepare cell/tissue lysates in RIPA buffer with protease inhibitors

• Separate proteins by SDS-PAGE (expect TRAPPC5 band at approximately 21 kDa)

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with TRAPPC5 antibody at 1:1000 dilution overnight at 4°C

• Wash extensively with TBST

• Incubate with appropriate HRP-conjugated secondary antibody

• Develop using ECL substrate and image

Immunofluorescence

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

• Block with 3% BSA in PBS for 1 hour

• Incubate with TRAPPC5 antibody at 1:100-500 dilution overnight at 4°C

• Co-stain with Golgi markers (GM130) and/or other TRAPP complex proteins

• Apply fluorophore-conjugated secondary antibodies

• Counterstain nuclei with DAPI and mount

ELISA

• Coat plates with capture antibody or sample containing TRAPPC5

• Block non-specific binding with 3% BSA in PBS

• Incubate with TRAPPC5 antibody at 1:5000 dilution

• Apply appropriate HRP-conjugated secondary antibody

• Develop with TMB substrate and measure absorbance at 450 nm

How can I optimize TRAPPC5 antibody-based detection in tissues with low expression levels?

Detecting TRAPPC5 in tissues with low expression requires specialized approaches:

• Signal amplification methods:

  • Implement tyramide signal amplification (TSA) which can increase sensitivity 10-100 fold

  • Use polymer-based detection systems which provide multiple HRP molecules per bound antibody

  • Consider rolling circle amplification (RCA) for extreme sensitivity in immunofluorescence

• Tissue preparation optimization:

  • Test multiple antigen retrieval methods (citrate, EDTA, Tris-EDTA at different pH values)

  • Extend antigen retrieval time to 30-40 minutes for difficult tissues

  • Consider low-temperature antigen retrieval methods for sensitive epitopes (37°C overnight)

• Antibody incubation modifications:

  • Extend primary antibody incubation to 48-72 hours at 4°C

  • Use antibody incubation chambers to prevent evaporation during extended incubations

  • Consider signal enhancing buffers containing polymers that increase antibody binding efficiency

• Sample enrichment approaches:

  • Perform laser capture microdissection to isolate specific regions with higher expression

  • Use thicker tissue sections (6-10 μm) to increase the amount of antigen present

  • Consider tissue microarrays to screen multiple samples simultaneously

• Detection system sensitivity:

  • For fluorescence, use high-sensitivity cameras and longer exposure times

  • Employ spectral unmixing to distinguish true signal from autofluorescence

  • For chromogenic detection, use amplification substrates and longer development times

• Validation controls:

  • Include positive control tissues known to express TRAPPC5

  • Run parallel negative controls with pre-immune serum or isotype control antibodies

  • Consider using TRAPPC5-overexpressing tissue samples as reference standards

What are the key considerations for developing co-localization experiments between TRAPPC5 and other TRAPP complex components?

Co-localization experiments between TRAPPC5 and other TRAPP complex components require careful planning:

• Antibody compatibility:

  • Select primary antibodies raised in different host species to avoid cross-reactivity

  • If using antibodies from the same species, implement sequential staining with intermediate blocking steps

  • Validate each antibody individually before combining in co-localization experiments

• Fixation and permeabilization optimization:

  • Test different fixatives (4% PFA, methanol, or combinations) as different TRAPP components may require different conditions

  • Optimize permeabilization to ensure accessibility to all cellular compartments where TRAPP components localize

  • Consider mild permeabilization for membrane-associated complexes to preserve structural integrity

• Microscopy specifications:

  • Use confocal or super-resolution microscopy for accurate co-localization assessment

  • Implement sequential scanning to minimize bleed-through between fluorescent channels

  • Set optimal pinhole size (0.7-1.0 Airy units) to achieve the best signal-to-noise ratio

• Controls for co-localization analysis:

  • Include positive controls: Known interacting proteins that should co-localize

  • Include negative controls: Proteins that occupy distinct cellular compartments

  • Use fluorescent protein standards to calibrate imaging parameters

• Quantitative co-localization analysis:

  • Apply appropriate co-localization algorithms (Pearson's correlation, Manders' coefficients)

  • Implement intensity correlation analysis to distinguish true co-localization from coincidental overlap

  • Use appropriate software (ImageJ with Coloc2, CellProfiler, Imaris) for quantitative assessment

• Dynamic co-localization studies:

  • Consider live-cell imaging using fluorescently tagged TRAPP components

  • Implement FRET or FLIM-FRET to assess direct protein-protein interactions

  • Use photoactivatable or photoconvertible tags to track subpopulations of TRAPP components

• Experimental conditions:

  • Assess co-localization under different cellular states (normal, stress, cell cycle phases)

  • Include drug treatments that affect membrane trafficking (e.g., Brefeldin A, nocodazole)

  • Consider analysis in disease models where TRAPP function may be altered

What methodological approaches should I use to compare TRAPPC5 function across different species models?

Comparative studies of TRAPPC5 across species require specialized approaches:

• Cross-species antibody validation:

  • Test TRAPPC5 antibody reactivity against recombinant proteins from different species

  • Perform epitope mapping to confirm conservation of the antibody-binding region

  • Include positive controls from each species in validation experiments

• Functional complementation assays:

  • Implement humanized yeast systems to test if human TRAPPC5 can replace its yeast ortholog TRS31

  • Note that unlike some TRAPP components (TRAPPC1, TRAPPC2, TRAPPC2L, TRAPPC6A, and TRAPPC6B), TRAPPC5 cannot complement the loss of its yeast ortholog TRS31

  • Use cross-species expression experiments in cell lines to assess functional conservation

• Interactome comparison:

  • Perform co-immunoprecipitation studies with TRAPPC5 from different species

  • Use mass spectrometry to identify species-specific interaction partners

  • Apply quantitative interaction proteomics to measure affinity differences across species

• Structural biology approaches:

  • Compare crystal or cryo-EM structures of TRAPP complexes from different species

  • Analyze species-specific differences in TRAPPC5 structure and complex assembly

  • Implement molecular dynamics simulations to assess functional implications of structural differences

• Evolutionary analysis:

  • Conduct phylogenetic analyses to trace TRAPPC5 evolution

  • Identify conserved functional domains vs. species-specific regions

  • Correlate evolutionary changes with functional adaptations in membrane trafficking

• Cross-species cellular assays:

  • Compare TRAPPC5 localization patterns across species using immunofluorescence

  • Assess membrane trafficking rates in cells from different species

  • Evaluate stress responses and TRAPPC5 relocalization in various model organisms

Utilizing these approaches will help establish which aspects of TRAPPC5 function are universally conserved versus those that have evolved species-specific adaptations.